low - Clinical-stage biotechs are largely insulated from GDP fluctuations as R&D spending is committed years in advance based on clinical trial protocols, not economic conditions. Patient enrollment in rare disease trials (AL amyloidosis affects ~4,000 new US patients annually) is driven by disease prevalence, not discretionary healthcare spending. However, severe recessions can impact ability to raise capital and partnership appetite from large pharma.

Rising interest rates negatively impact Prothena through two mechanisms: (1) Higher discount rates compress NPV of distant future cash flows, particularly punitive for pre-revenue assets with 5-10 year commercialization timelines, causing multiple compression across biotech sector; (2) Increased yields on risk-free alternatives (Treasuries, money markets) reduce investor appetite for speculative growth equities, driving capital away from clinical-stage names. The company's cash balance benefits modestly from higher short-term rates on invested capital, but this is overwhelmed by valuation impact. Current 10-year Treasury levels above 4% create significant headwinds versus 2020-2021 zero-rate environment.

growth - Prothena attracts speculative biotech investors focused on binary clinical catalysts and asymmetric risk/reward profiles. The stock appeals to healthcare-specialized funds, biotech-focused hedge funds running event-driven strategies around data readouts, and retail investors seeking high-risk/high-reward exposure to rare disease therapeutics. Not suitable for value or income investors given pre-revenue status, negative cash flow, and lack of dividends. Institutional ownership likely concentrated among healthcare specialists rather than generalist funds.